Seoul Bio Hub's resident company 'Oncomaster' has begun to advance into the Middle Eastern market by revealing its immune anticancer drug response prediction technology at the Abu Dhabi Industry Forum.
Precision medicine company OncoMASTER (CEO Wooyoung Jang) participated in the 'MAKE IT IN THE EMIRATES Forum 2025' held at the ADNEC exhibition center in Abu Dhabi, United Arab Emirates on May 20th and introduced 'OCM-002', an AI-based immune anticancer drug response prediction technology.
This forum is the largest industry and innovation event in the Middle East, hosted by the Ministry of Industry and Advanced Technology (MOIAT) of the United Arab Emirates, and is a place where global startups with next-generation technologies such as artificial intelligence, precision medicine, and advanced manufacturing gather together.
Oncomaster introduced 'OCM-002', an AI algorithm that integrates and analyzes NGS genome-based multi-omics and clinical data. This technology has garnered attention as a precision medicine solution that can overcome the current low response rate limit of approximately 30% by predicting the possibility of a patient's response to immunotherapy before treatment.
Starting with this announcement, OncoMaster plans to pursue collaboration with hospitals and medical institutions in the Middle East. Through joint research for clinical verification and commercialization, it will proceed with establishing a treatment strategy tailored to local patients. CEO Jang Woo-young said, “Although immunotherapy is a groundbreaking treatment, many patients are not seeing actual effects,” and “OncoMaster will be able to contribute to the innovation of precision medicine in the Middle East by suggesting the optimal treatment strategy for each patient through AI technology.”
In addition to immunotherapy, Oncomaster is also developing a model for predicting anticancer chemotherapy responses. Based on this, the company is expanding its business to developing a clinical decision support system (CDSS), discovering biomarkers, and conducting joint research with global pharmaceutical companies. In April, it was selected as one of the Ministry of SMEs and Startups’ “Super Gap Startup 1000+,” and is accelerating the advancement of AI precision medicine solutions as a national strategic technology.
This growth is also the result of the practical support of the 'Seoul Bio Hub'. During the period of residence, we were able to systematically proceed with strategy formulation, document work, and overseas expansion preparation by utilizing various facilities such as conference rooms and lounges. Oncomaster plans to continue to grow into a globally competitive company in the field of AI precision medicine.
- See more related articles
You must be logged in to post a comment.